Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY5.57
+0.18 (+3.34%)
CN SHZ Healthcare Medical - Specialties
Address
D5-3-3-4, North High-tech Zone 521000
Chaozhou, JS, CN
Chaozhou, JS, CN
CEO
Qiao Zhong Guan
Website
hybribio.cn
IPO
2017-04-13
ISIN CNE100002N51
Description
Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. It also provides on-site technical training and after-sales technical service support. The company was founded by Qiao Zhong Guan on June 13, 2003 and is headquartered in Chaozhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY5.57
+0.18 (+3.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
25M
Beta
0.47
Float Shares
616.55M
Free Float %
95.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.00% | -7.10% | -4.95% | -14.79% | -2.87% | +7.06% | +2.86% | -37.73% | -59.80% | +46.94% | +46.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
5.57
DCF (Unlevered)
0.12
-97.8%
DCF (Levered)
1.82
-67.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.84
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-18.4% Q1'26: -6.1% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+79.4% ★ Q1'26: +88.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+24.0% Q1'26: +5.7% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%-29.1% Q1'26: -20.8% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%-7.1% Q1'26: -3.7% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%-2.3% ★ Q1'26: -8.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-5.54× Q1'26: -0.84× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
479.09M
est: 470.00M (+1.9%)
|
580.35M
est: 574.00M (+1.1%)
|
729.39M
est: 738.51M (-1.2%)
|
1.35B
est: 1.36B (0.0%)
|
2.54B
est.
|
2.67B
est: 5.50B (-51.4%)
|
1.10B
est: 1.22B (-9.1%)
|
5.60B
est: 1.22B (+360.7%)
|
815.53M
est: 1.15B (-29.3%)
|
665.17M
est: 2.66B (-75.0%)
|
3.05B
3.05B – 3.05B
+14.5% YoY
|
3.54B
3.54B – 3.54B
+16.2% YoY
|
| EBITDA |
136.88M
est: 59.06M (+131.8%)
|
157.07M
est: 72.13M (+117.8%)
|
195.74M
est: 92.81M (+110.9%)
|
514.82M
est: 170.28M (+202.3%)
|
318.94M
est.
|
1.15B
est: 691.10M (+65.8%)
|
208.47M
est: 152.68M (+36.5%)
|
2.31B
est: 152.68M (+1,409.7%)
|
-673.15M
est: 41.41M (-1,725.7%)
|
-16.17M
est: 95.56M (-116.9%)
|
109.46M
109.46M – 109.46M
+14.5% YoY
|
127.20M
127.20M – 127.20M
+16.2% YoY
|
| EBIT |
109.52M
est: 13.62M (+704.0%)
|
126.31M
est: 16.64M (+659.3%)
|
154.54M
est: 21.40M (+622.0%)
|
464.78M
est: 39.27M (+1,083.6%)
|
73.55M
est.
|
1.06B
est: 159.38M (+567.9%)
|
42.91M
est: 35.21M (+21.9%)
|
2.14B
est: 35.21M (+5,971.2%)
|
-830.69M
est: -108.78M (-663.7%)
|
-193.42M
est: -251.04M (+23.0%)
|
-287.55M
-287.55M – -287.55M
-14.5% YoY
|
-334.16M
-334.16M – -334.16M
-16.2% YoY
|
| Net Income |
93.21M
est: 90.26M (+3.3%)
|
114.08M
est: 106.41M (+7.2%)
|
147.29M
est: 156.57M (-5.9%)
|
362.66M
est: 351.16M (+3.3%)
|
807.55M
est.
|
852.16M
est: 1.89B (-54.8%)
|
140.47M
est: 218.29M (-35.6%)
|
1.73B
est: 218.29M (+690.7%)
|
-654.88M
est: 138.04M (-574.4%)
|
-130.94M
est: 12.55M (-1,143.4%)
|
56.47M
56.47M – 56.47M
+350.0% YoY
|
87.85M
87.85M – 87.85M
+55.6% YoY
|
| SGA |
260.37M
est: 112.48M (+131.5%)
|
317.77M
est: 137.37M (+131.3%)
|
381.22M
est: 176.74M (+115.7%)
|
445.73M
est: 324.28M (+37.5%)
|
607.40M
est.
|
581.70M
est: 1.32B (-55.8%)
|
532.48M
est: 290.78M (+83.1%)
|
847.68M
est: 290.78M (+191.5%)
|
482.00M
est: 449.31M (+7.3%)
|
336.72M
est: 1.04B (-67.5%)
|
1.19B
1.19B – 1.19B
+14.5% YoY
|
1.38B
1.38B – 1.38B
+16.2% YoY
|
| EPS |
0.17
est: 0.14 (+20.9%)
|
0.19
est: 0.17 (+14.6%)
|
0.25
est: 0.24 (+2.5%)
|
0.59
est: 0.55 (+7.9%)
|
1.26
est.
|
1.29
est: 2.94 (-56.1%)
|
0.25
est: 0.34 (-26.5%)
|
2.62
est: 0.34 (+670.6%)
|
-1.02
est: 0.22 (-563.6%)
|
-0.21
est: 0.02 (-1,150.0%)
|
0.09
0.09 – 0.09
+350.0% YoY
|
0.14
0.14 – 0.14
+55.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
134.20M
OE per share TTM
0.21
Owner's Yield
3.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
59.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 9.1K | 0.46% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 2.4K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 1.1K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 120.6K | 0.06% |
| 5 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 193.76 | 0.22% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 584.05 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 313.88 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 138.38 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 15.99 | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 5.24 | 0.31% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-87.7K
Shares Outstanding
646.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cuihong Luo | Accounting Supervisor | — | — |
| Danrong Weng | Deputy General Manager | — | female |
| Jianyu Wang | GM & Director | — | female |
| Longxu Xie | Deputy GM & Director | — | male |
| Qinghui Li | Financial Director | — | male |
| Xiaochuan Li | Chief Medical Officer | — | male |
| Yi Chen | Deputy GM & Board Secretary | — | male |
| Zhisheng Guan | Executive Deputy GM & Non Independent Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300639.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
